Xbrane Secures Patents For Low-Cost Biosimilar Production
Company Plans To Build On Swedish Patents With International Applications
Xbrane Biopharma has celebrated after being granted two Swedish patents covering its “high-yield” protein expression platform that the biosimilars specialist expects to act as the basis for international applications.
You may also be interested in...
Xbrane Joins Forces With Contract Manufacturer For Cimzia Biosimilar
Sweden’s Xbrane Biopharma has secured a manufacturing partner in its native Scandinavia, Denmark’s AGC Biologics, to help complete key steps for its proposed Xcimzane (certolizumab pegol) biosimilar to Cimzia ahead of Phase I and Phase III clinical trials.
Xbrane And Stada Celebrate Major Milestone With EU Filing For Lucentis Rival
Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.
Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.